Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant700 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,395 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03541720 | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | active not recruiting | Early Phase 1 | 13 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04702880 |
| A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer |
| completed |
| Phase 2 |
| 135 |
| Bristol-Myers SquibbINDUSTRY |
| 11 |
| Jun 17, 2026 |
| clinicaltrials |
| NCT07473128 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | recruiting | Phase 3 | 120 | Pharmacosmos A/SINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT00453154 | Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05683977 | A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.(ARSENAL) | active not recruiting | — | 254 | AstraZenecaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06501976 | An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment | active not recruiting | Phase 2 | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03271372 | Adjuvant Avelumab in Merkel Cell Cancer(ADAM) | active not recruiting | Phase 3 | 101 | University of WashingtonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04750954 | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors | active not recruiting | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05257551 | Tempus Small Cell Lung Cancer Observational Study (Sculptor) | recruiting | — | 200 | Tempus AIINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06041516 | A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors | recruiting | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04705389 | SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines(SUMMERTIME) | active not recruiting | N/A | 35 | University Hospital, ToursOTHER | 10 | Jun 12, 2026 | clinicaltrials |
| NCT06091748 | Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06957314 | A Study of Hospital-at-Home for People Receiving Tarlatamab | recruiting | N/A | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04155034 | S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | active not recruiting | Phase 3 | 668 | SWOG Cancer Research NetworkNETWORK | 7 | Jun 11, 2026 | clinicaltrials |
| NCT04728230 | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | active not recruiting | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06158516 | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 6 | Changhai HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06204159 | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery(Trinav) | active not recruiting | N/A | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07091305 | A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05419076 | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06788886 | Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases | recruiting | N/A | 147 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | recruiting | Phase 2 | 90 | Jazz PharmaceuticalsINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02134639 | PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation(GALTEP) | completed | Phase 1 | 20 | University Hospital, BordeauxOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT07267000 | EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER(ImmuEX) | recruiting | N/A | 50 | Medical University of GrazOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07637513 | Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer(PrE0512) | not yet recruiting | Phase 3 | 430 | PrECOG, LLC.OTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT04510311 | Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors | completed | Early Phase 1 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | recruiting | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632209 | Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment(Aurora003) | not yet recruiting | Phase 2 | 46 | Yayi HeOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT04334941 | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | active not recruiting | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | recruiting | Phase 2 | 37 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04339036 | CapTemY90 for Grade 2/3 NET Liver Metastases(CapTemY90) | recruiting | Phase 2 | 70 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04954820 | Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET(ReLUTH) | recruiting | Phase 2 | 146 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | recruiting | Phase 1 | 150 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07612748 | Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms | recruiting | N/A | 483 | Jilin UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619417 | Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms | not yet recruiting | N/A | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07621146 | A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies(NET-COMPARE) | not yet recruiting | — | 51 | British Columbia Cancer AgencyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04938817 | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | active not recruiting | Phase 1 / Phase 2 | 110 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07618949 | Standardized Patient Education in Pituitary Surgery | not yet recruiting | N/A | 102 | Uludag UniversityOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT00107289 | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | recruiting | Phase 2 | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02688036 | Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC | completed | Phase 3 | 860 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials